Gossamer Bio (GOSS) investor relations material

Key milestones and clinical progress

• Awaiting phase 3 readout for PROSERA study in pulmonary arterial hypertension (PAH) in February next year, expected to be a major catalyst for regulatory approval and commercialization globally with Chiesi.

• Plans to initiate a phase 3 trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) by year-end, targeting a market two to three times larger than PAH with minimal competition.

• Potential for two commercial launches before the end of the decade in a market exceeding $20 billion.

Clinical strategy and differentiation

• Enrolled a sicker patient population in PROSERA phase 3 using enrichment strategies and targeted geographies to maximize efficacy and probability of success.

• Seralutinib demonstrated best-in-class safety and durable efficacy in phase 2 and open-label extension, with minimal side effects compared to current market leader sotatercept.

• Positioned as the next most-used branded drug after generics in the PAH treatment paradigm, aiming to disrupt a static market.

Pipeline expansion and complementary assets

• Option to acquire Respira Therapeutics and RT234, an inhaled on-demand vardenafil therapy, to supplement chronic seralutinib treatment and improve patient quality of life.

• RT234 offers rapid relief for PAH patients during daily activities, complementing seralutinib's long-term disease management.